Remdesivir- Dexolve formulation in the space – a book of NASA

Posted by

In the annual report of NASA there is a great recognition of benefits of cyclodextrin technology even in space chemistry. It is recommend to read text on page 53 on remdesivir- Dexolve formulation used in Veklury product.

One experiment launched to the space station in December 2020 examined the efficiency of remdesivir, an intravenous antiviral drug currently approved by the Food and Drug Administration (FDA) for the treatment of COVID-19 in hospitalized patients. Using a commercially owned and operated research facility, Europe’s International Commercial Experiment Cubes (ICE Cubes), researchers from ESA (European Space Agency) tested the drug’s behavior in microgravity with the goal of increasing its efficiency. 

Studying the interactions between remdesivir and cyclodextrin in microgravity could allow researchers to enhance the ratio of the drug to cyclodextrin. Decreasing the amount of cyclodextrin in the IV bag reduces the risk to coronavirus-infected patients with pre-existing kidney problems.

The ESA ICE Cubes facility in the Columbus European Physiology Module where an experiment to improve the ratio of the antiviral drug remdesivir to a solubility agent could make it safer to administer to patients with pre-existing health issues such as kidney failure. Credit: NASA

Leave a Reply

This site uses Akismet to reduce spam. Learn how your comment data is processed.